117 related articles for article (PubMed ID: 37140101)
1. A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells.
Aguilar-Valdés A; González-Vela F; Sánchez-Vidal H; Martínez-Aguilar J
Proteomics; 2023 Aug; 23(16):e2300041. PubMed ID: 37140101
[TBL] [Abstract][Full Text] [Related]
2. SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Aguilar-Valdés A; Noriega LG; Tovar AR; Ibarra-Sánchez MJ; Sosa-Hernández VA; Maravillas-Montero JL; Martínez-Aguilar J
Biochem Biophys Res Commun; 2021 May; 552():23-29. PubMed ID: 33740661
[TBL] [Abstract][Full Text] [Related]
3. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
[TBL] [Abstract][Full Text] [Related]
4. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
5. KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.
Althaiban A; Thyagarajan A; Sahu RP
Mini Rev Med Chem; 2023; 23(8):953-961. PubMed ID: 36573057
[TBL] [Abstract][Full Text] [Related]
6. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
8. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
13. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
[TBL] [Abstract][Full Text] [Related]
14. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
Hayes TK; Neel NF; Hu C; Gautam P; Chenard M; Long B; Aziz M; Kassner M; Bryant KL; Pierobon M; Marayati R; Kher S; George SD; Xu M; Wang-Gillam A; Samatar AA; Maitra A; Wennerberg K; Petricoin EF; Yin HH; Nelkin B; Cox AD; Yeh JJ; Der CJ
Cancer Cell; 2016 Jan; 29(1):75-89. PubMed ID: 26725216
[TBL] [Abstract][Full Text] [Related]
15. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
17. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
18. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
